Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06935591 · ClinicalTrials.gov registry record · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
A NA study of Atrial Fibrillation (AF), sponsored by Vektor Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 423
- Enrollment target
- 13
- Study locations
NCT06935591: Recruiting NA study of Atrial Fibrillation (AF), sponsored by Vektor Medical.
NCT06935591 is a NA study of Atrial Fibrillation (AF) that is actively recruiting participants, run by Vektor Medical. The registered enrollment target is 423 participants, below the 695-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (39% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06935591, a NA study of Atrial Fibrillation (AF), is actively recruiting participants, sponsored by Vektor Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 423 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or control arm. The control arm of the study involves PVI alone for ablation procedure(s). The treatment arm involves the use of vMap mapping in addition to PVI to plan ablation procedure(s).
Primary Outcome
The achievement of freedom from AF for subjects on or off antiarrhythmic drug (AAD) therapy at 12 months.
Conditions Studied
Interventions
- PROCEDURE Pulmonary Vein Isolation
- DEVICE vMap® + Pulmonary Vein Isolation
Study Locations (13)
Florida
- BayCare Health System - Clearwater
- Baptist Health Jacksonville - Jacksonville
- USF Health - Tampa
Georgia
- Piedmont Heart of Athens - Athens
- Piedmont Heart Institute - Atlanta
Ohio
- OhioHealth - Columbus
- University of Toledo Medical Center - Toledo
Arkansas
- Arrhythmia Research Group - St. Bernards - Jonesboro
Indiana
- Indiana University - Indianapolis
Kentucky
- Baptist Health Lexignton - Lexington
New York
- Westchester Medical Center - Valhalla
Pennsylvania
- Penn Presbyterian - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT06935591 shows while recruiting
NCT06935591 is an interventional study that assigns participants to a tested intervention. The registered 423 participants enrollment target is mid-sized for trials with a published cap, below the 695-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 2 interventions - of which Pulmonary Vein Isolation is the first listed.
NCT06935591 lists 13 locations in 9 states (Florida, Georgia, Ohio).
Frequently Asked Questions
What is clinical trial NCT06935591 about?
NCT06935591 is a clinical study titled "Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study". The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or ...
What is the current status of trial NCT06935591?
This trial is currently recruiting. It is a NA study. The enrollment target is 423 participants. The study started on 2025-06-27. Estimated completion is 2027-12.
What conditions does trial NCT06935591 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF).
What interventions are being tested in trial NCT06935591?
The interventions under investigation include: Pulmonary Vein Isolation (PROCEDURE), vMap® + Pulmonary Vein Isolation (DEVICE).
Who is sponsoring clinical trial NCT06935591?
This trial is sponsored by Vektor Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06935591 being conducted?
This trial has 13 study locations across Arkansas, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation (AF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06935591's enrollment target sits among peer trials
423 10th of 17 higher than 8 of 17 other Atrial Fibrillation (AF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation (AF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
RECRUITING · NA
-
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
RECRUITING · NA
-
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
RECRUITING · NA
-
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
RECRUITING · NA
-
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
RECRUITING · NA
-
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07128628 · 423 participants · Phase 2
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI